However, in another study related to oncogenic KRAS, KRAS mutations triggered enhanced ADAM17-mediated NPG1 shedding of the SLC3A2-NPG1 fusion protein, which in turn promoted tumor cell growth (10). The gene discussed is ADAM17; the disease is neoplasm.